Diamedica Therapeutics (DMAC) has released an update.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Diamedica Therapeutics Inc. has filed a Form 8-K with the SEC, detailing a current report that could impact its stock, traded under the symbol DMAC on The Nasdaq Stock Market LLC. The report, dated May 8, 2024, pertains to the company, headquartered in Minneapolis, Minnesota, which is not classified as an emerging growth company.
For further insights into DMAC stock, check out TipRanks’ Stock Analysis page.
